Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PYGB | P11216 | 7/20 | 0.37 |
| ▸ | PYGL | P06737 | 3/20 | 0.37 |
| ▸ | PYGM | P11217 | 2/20 | 0.37 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | GBA1 | P04062 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19242663 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL6376667 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2853265 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8522586 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969252 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL12689155 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL2857459 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL9006 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL10013929 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959591 | 1.00 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150216985-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | Annuary Healthcare Inc. | 2015-08-06 | — | — | US | claimed |
| EP-4045182-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045180-A1 | DEVICE FOR AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-20150216985-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | Annuary Healthcare Inc. | 2015-08-06 | — | — | US | disclosed |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140178496-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | Annuary Healthcare Inc. | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216985-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | CUTA, SUCLG1, CD47 | MEN1 2446/4885KMT2A 3655/4885PYGB 408/4885 |
| US-20140178496-A1 | ENDOSPORE COMPOSITIONS AND USES THEREOF | CUTA, SUCLG1, CD47 | MEN1 2446/4885KMT2A 3655/4885PYGB 408/4885 |
| US-20140286943-A1 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR | P2RY12, P2RY11, P2RY2 | MEN1 4315/4885KMT2A 4533/4885PYGB 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.